Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group Inc. (CME) reported an insider transaction: Director Harold Ford Jr. sold 1,000 Class A shares on November 3, 2025, coded S (open market sale). The weighted average sale price was $263.53, with a price range of $263.21–$263.68.
Following the sale, he directly owns 1,091 shares. The company notes prices within a $1 range were aggregated and maintains detailed records available upon request.
CME Group Inc. reported Q3 2025 results with total revenue of $1,537.6 million versus $1,584.4 million a year ago as lower futures and options activity reduced clearing and transaction fees. Operating income was $972.6 million with a 63.3% operating margin. Net income was $908.0 million, and diluted EPS was $2.49.
Market data and information services grew to $202.5 million (up 14% year over year), partly offsetting softer trading revenues. Non‑operating income of $204.4 million reflected high investment income driven by reinvestment of performance bond collateral, net of distributions to clearing members.
Year‑to‑date, operating cash flow reached $3,143.2 million. The company paid dividends of $1.25 per share in Q3 (total $3.75 per share YTD) and repurchased 32,265 shares for $8.2 million. CME refinanced debt—retiring $750.0 million due 2025 and adding $750.0 million due 2030—bringing long‑term debt to $3,421.3 million. Subsequent event: on October 10, 2025, CME and S&P Global completed the sale of OSTTRA (EV $3.1 billion split 50/50); CME expects to recognize a ~$300.0 million gain in Q4 2025.
CME Group Inc. furnished an 8-K announcing quarterly results. The company reported that a press release dated October 22, 2025, covering financial results for the quarter ended September 30, 2025, was furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
The press release includes non-GAAP measures—revenues, expenses, operating income, net income, and earnings per share—with reconciliations to the most comparable GAAP metrics pursuant to Regulation G. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act.
Jonathan L. Marcus, Senior Managing Director and General Counsel at CME Group Inc. (CME), reported a sale of 392 shares of Class A common stock on 09/18/2025 at a reported price of $262 per share. The filing shows the transaction was executed under a Rule 10b5-1 trading plan adopted on February 18, 2025. After this sale the reporting person beneficially owns 7,851 shares of Class A common stock. The Form 4 is singularly filed for one reporting person and was signed by Margaret Austin Wright on behalf of Jonathan L. Marcus.
Form 144 notice for CME Group Inc. (CME) shows a proposed sale of 392 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $102,704.00 and an approximate sale date of 09/18/2025 on NASDAQ. The securities were acquired from the issuer as restricted stock on 09/16/2025 and payment was recorded as 09/16/2025. The filing also reports prior transactions: the person for whose account the sale is filed sold 376 shares on 09/16/2025 for gross proceeds of $97,368.96. The filing includes the required representation that the signer does not possess undisclosed material adverse information.
Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME), reported share transactions on Form 4 tied to restricted stock vesting. On 09/15/2025 he surrendered 1,117 Class A shares at $258.83 per share to satisfy tax withholding and later received 3,044 shares at the same price, leaving him with 19,367 Class A shares after that trade. On 09/16/2025 he surrendered 379 Class A shares at $259.83 for tax withholding, resulting in 18,988 shares held. The filing is signed on behalf of Mr. Cutinho on 09/17/2025 and lists these transactions as related to vesting and tax obligations.
Julie Winkler, Senior Managing Director and Chief Commercial Officer at CME Group (CME), reported insider transactions related to restricted stock vesting and tax-withholding on September 15-16, 2025. On 09/15/2025 she surrendered 1,081 shares at $258.83 to satisfy tax withholding upon vesting and received 3,044 shares at $258.83 from the vesting event, and on 09/16/2025 she surrendered 379 shares at $259.83 for tax withholding. After these transactions she beneficially owned 25,512 Class A shares. The Form 4 was signed on behalf of Ms. Winkler by Margaret Austin Wright on 09/17/2025. The filing shows routine equity vesting and share-withholding to cover taxes; no derivative transactions or additional compensatory arrangements are disclosed in this Form 4.
Kendal L. Vroman, Chief Transformation Officer of CME Group Inc. (CME), reported insider transactions on a Form 4 showing restricted stock vesting and related tax withholding. On 09/15/2025 he surrendered 971 Class A shares to the company at a reported price of $258.83 to satisfy tax withholding and, on the same day, was recorded as acquiring 2,608 Class A shares at $258.83, bringing his beneficial ownership to 20,395 shares. On 09/16/2025 he surrendered an additional 325 Class A shares at $259.83, leaving 20,070 shares reported as beneficially owned. The form states the surrenders were to fulfill tax withholding obligations upon vesting of restricted stock.
CME Group insider Jonathan L. Marcus reported routine equity transactions in mid-September 2025. On September 15, 2025 he surrendered 259 Class A shares to the company to satisfy tax-withholding obligations related to restricted stock vesting, and on the same day he acquired 2,464 Class A shares at a price of $258.83 per share, leaving him with 8,913 shares beneficially owned. On September 16, 2025 he sold 376 Class A shares at $258.96 under a Rule 10b5-1 plan adopted February 18, 2025, and surrendered an additional 259 shares at $259.83 for tax withholding, resulting in 8,243 shares owned after those transactions. The filing is signed for Mr. Marcus on September 17, 2025.
Suzanne Sprague, COO & Global Head of Clearing of CME Group Inc. (CME), reported stock transactions related to the vesting of restricted shares. On 09/15/2025 she surrendered 639 Class A shares to the company to satisfy tax withholding upon vesting and simultaneously acquired 3,044 Class A shares, leaving her with 11,172 Class A shares after those transactions. On 09/16/2025 she surrendered an additional 325 Class A shares for tax withholding, leaving 10,847 Class A shares reported as beneficially owned.
The Form 4 indicates these transactions were to meet tax obligations tied to restricted stock vesting; no cash purchases or open-market sales are reported and no derivative transactions are disclosed.